A technique to measure immunoreactive human atrial natriuretic polypeptide (IR-hANP) in plasma was developed using immuno-affinity chromatography for extraction. In normal subjects, the plasma IR-hANP level was 25i 15 pg/ml (mean i SD; ranged from 9 to 65 pg/ml, n=40). The level in patients with angina pectoris without overt heart failure was 19 i 8.7 pg/ml (mean i SD; ranged from 8 to 32 pg/ml, n=l4). The level was markedly elevated in patients with heart failure (340 i 230 pg/ml, mean i SD; ranged from 110 to 920 pg/ml, n=l8), and with chronic renal failure (160 i 94 pg/ml, mean i SD; ranged from 65 to 310 pg/ml, n=6). Sephadex G-50 gel filtration studies revealed that plasma IR-hANP was composed of at least 3 peaks; a macromolecular form, a-hANP and its fragment. There was no significant difference in molecular size heterogeneity of plasma IR-hANP between normal subjects and patients with heart failure or with chronic renal failure. Three polypeptide species called or-, 5-and yhuman atrial natriuretic polypeptide (hANP) were isolated from human atrium (4, 5). These polypeptides seem to be involved in the regulation of extracellular fluid volume.
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In the present work, we investigated the plasma immunoreactive hANP (IR-hANP) level by a newly developed method using immuno-affinity chromatography, and the molecular size heterogeneity of plasma IR-hANP in normal subjects and patients with heart or renal diseases.
MATERIALS AND METHODS .

Materials
The following materials were obtained from Reprint requests to Dr Kaoru Abe, Endocrinology Division, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuoku, Tokyo 104, Japan the sources indicated. oz-hANP, a-hANP[l-11], a-hANP[7-28], a-hANP[13-28] and a-hANP [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] were from Peninsula Laboratories, (Belmont, CA, U.S.A.); [Met(O)'2]-a-hANP, a-hANP[4-28], a-hANP[5-28], a-hANP[5-27] and a-rat ANP (a-rANP) were from Peptide Research Foundation (Osaka, Japan); activated CH-Sepharose 4B and Sephadex G-50 superfine were from Pharmacia Fine Chemicals AB (Uppsala, Sweden); Naml and "SI-human albumin were from New England Nuclear (Boston, MA, U.S.A.); porcine thyroglobulin was from Sigma Chemicals (St. Louis, MO, U.S.A.); Trasylol was from Bayer (Leverkusen, F.R.G.); bovine serum albumin (Cohn Fraction V) was from Dai-ichi Pure Chemicals (Osaka, Japan); "SIoz-hANP with specific activity of about 2,000 Ci/mmol was from Amersham International (Buckinghamshire, U.K.).
